ARTIDIS
Basel
About ARTIDIS
ARTIDIS's nanomechanical sensor captures the physical properties of tissue enabling the clinician to differentiate between benign and malignant tissue in under three hours. In addition, the technology allows the clinician to define the aggressiveness of the tumor with very high accuracy based on the nanomechanical signature of the cells. Only very soft cells can squeeze through all different tissues to create distant metastases that are responsible for more than 90% of cancer related deaths. The nano-probe measures the tissue’s physical properties allowing us to discover robust nano-mechanical biomarkers and predict disease development. Moreover, ARTIDIS technology is not limited to cancer and can analyze any living tissue.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $42.4M
- Funding stage: Early Stage Venture
- Last round: Series A (May 2023)
- Website: artidis.com
- Phone: +41 61 633 29 94
Industries & Categories
Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/artidis-56016 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.